The Global Health Body Sounds Concern Over Severe Lack of Obesity Medications
Under one in 10 patients who could benefit from weight-loss injections such as Wegovy are able to get them, warns the global health agency as it publishes its first guidance on the therapies.
With more than one billion people worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.
Based on forecasts, more than two billion will be obese by 2030 if no action is taken.
"Our new guidelines acknowledges that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant barriers to universal access to the jabs that can assist patients in reducing considerable weight, explains the agency.
Skinny Jab Shortage
Even under the present most favorable case, the manufacturing of these medications might only reach around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on countries and companies to expand availability, via measures like patent sharing.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and enhance satiety so users eat less.
Patients typically see weight reduction in the initial weeks of starting on the weekly injections.
Evidence points to users may regain a significant portion within a year of halting the treatment, as their usual food cravings come back.
Being carrying excess weight raises your risk for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns people in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
